Search Results - "BLAY, J"

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor by Henon, C., Blay, J.-Y., Massard, C., Mir, O., Bahleda, R., Dumont, S., Postel-Vinay, S., Adam, J., Soria, J.-C., Le Cesne, A.

Get full text

Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19 by Solodky, M.L., Galvez, C., Russias, B., Detourbet, P., N’Guyen-Bonin, V., Herr, A.-L., Zrounba, P., Blay, J.-Y.

Get full text

Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Casali, P. G., Blay, J.-Y.

Get full text

Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients by Heudel, P., Favier, B., Assaad, S., Zrounba, P., Blay, J.-Y.

Get full text

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Casali, P. G., Blay, J.-Y.

Get full text

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study by Le Cesne, A., Marec-Berard, P., Blay, J.-Y., Gaspar, N., Bertucci, F., Penel, N., Bompas, E., Cousin, S., Toulmonde, M., Bessede, A., Fridman, W.H., Sautes-Fridman, C., Kind, M., Le Loarer, F., Pulido, M., Italiano, A.

“…There are some lines of evidence suggesting a potential role of immunotherapy for treating patients with osteosarcomas. This was an open-label, multicentre,…”
Get full text

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages by Gomez-Roca, C.A., Italiano, A., Le Tourneau, C., Cassier, P.A., Toulmonde, M., D’Angelo, S.P., Campone, M., Weber, K.L., Loirat, D., Cannarile, M.A., Jegg, A.-M., Ries, C., Christen, R., Meneses-Lorente, G., Jacob, W., Klaman, I., Ooi, C.-H., Watson, C., Wonde, K., Reis, B., Michielin, F., Rüttinger, D., Delord, J.-P., Blay, J.-Y.

“…Emactuzumab is a monoclonal antibody against the colony-stimulating factor-1 receptor and targets tumor-associated macrophages (TAMs). This study assessed the…”
Get full text

Why will there never be a randomized trial for NTRK-rearranged tumors? by Penel, N., Lebellec, L., Blay, J.-Y.

“…The optimal assessment of the risk-to-benefit ratio of a new treatment, particularly in oncology, has always been based on the results of prospective…”
Get full text

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’ by Schöffski, P., Wozniak, A., Kasper, B., Aamdal, S., Leahy, M.G., Rutkowski, P., Bauer, S., Gelderblom, H., Italiano, A., Lindner, L.H., Hennig, I., Strauss, S., Zakotnik, B., Anthoney, A., Albiges, L., Blay, J.-Y., Reichardt, P., Sufliarsky, J., van der Graaf, W.T.A., Debiec-Rychter, M., Sciot, R., Van Cann, T., Marréaud, S., Raveloarivahy, T., Collette, S., Stacchiotti, S.

“…Alveolar soft part sarcoma (ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3 (TFE3), leading to abnormal MET gene…”
Get full text

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ by Schöffski, P., Wozniak, A., Stacchiotti, S., Rutkowski, P., Blay, J.-Y., Lindner, L.H., Strauss, S.J., Anthoney, A., Duffaud, F., Richter, S., Grünwald, V., Leahy, M.G., Reichardt, P., Sufliarsky, J., van der Graaf, W.T., Sciot, R., Debiec-Rychter, M., van Cann, T., Marréaud, S., Lia, M., Raveloarivahy, T., Collette, L., Bauer, S.

“…Clear-cell sarcoma (CCSA) is an orphan malignancy, characterized by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and…”
Get full text

Improving at a nationwide level the management of patients with sarcomas with an expert network by Blay, J.-Y., Penel, N., Gouin, F., Le Cesne, A., Toulmonde, M.

Get full text

Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE by Gaspar, N., Marshall, L.V., Binner, D., Herold, R., Rousseau, R., Blanc, P., Capdeville, R., Carleer, J., Copland, C., Kerloeguen, Y., Norga, K., Pacaud, L., Sevaux, M.-A., Spadoni, C., Sterba, J., Ligas, F., Taube, T., Uttenreuther-Fischer, M., Chioato, S., O'Connell, M.A., Geoerger, B., Blay, J.-Y., Soria, J.C., Kaye, S., Wulff, B., Brugières, L., Vassal, G., Pearson, A.D.J.

Get full text

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up by Penel, N., Le Cesne, A., Bui, B.N., Perol, D., Brain, E.G., Ray-Coquard, I., Guillemet, C., Chevreau, C., Cupissol, D., Chabaud, S., Jimenez, M., Duffaud, F., Piperno-Neumann, S., Mignot, L., Blay, J.-Y.

“…Imatinib evaluated as a new treatment option in patients with recurrent or established progressive aggressive fibromatosis/desmoid tumor (AF/DT). Forty…”
Get full text

Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up by Casali, P. G., Jost, L., Reichardt, P., Schlemmer, M., Blay, J.-Y.

Get full text

Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—an EORTC STBSG and ROG study (EORTC 62991–22998) by Keus, R.B., Nout, R.A., Blay, J.-Y., de Jong, J.M., Hennig, I., Saran, F., Hartmann, J.T., Sunyach, M.P., Gwyther, S.J., Ouali, M., Kirkpatrick, A., Poortmans, P.M., Hogendoorn, P.C.W., van der Graaf, W.T.A.

“…To determine the activity of radiotherapy in patients with inoperable desmoid-type fibromatosis (DF) a multicenter prospective phase II trial was carried out…”
Get full text

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort by Italiano, A., Bessede, A., Pulido, M., Bompas, E., Piperno-Neumann, S., Chevreau, C., Penel, N., Bertucci, F., Toulmonde, M., Bellera, C., Guegan, J. P., Rey, C., Sautès-Fridman, C., Bougoüin, A., Cantarel, C., Kind, M., Spalato, M., Dadone-Montaudie, B., Le Loarer, F., Blay, J. Y., Fridman, W. H.

“…Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that…”
Get full text

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib by Reichardt, P., Blay, J.-Y., Gelderblom, H., Schlemmer, M., Demetri, G.D., Bui-Nguyen, B., McArthur, G.A., Yazji, S., Hsu, Y., Galetic, I., Rutkowski, P.

“…This phase III open-label trial investigated the efficacy of nilotinib in patients with advanced gastrointestinal stromal tumors following prior imatinib and…”
Get full text

Updating progress in sarcoma therapy with mTOR inhibitors by Blay, J.-Y.

“…Sarcomas are a diverse group of difficult-to-treat connective tissue neoplasms. The mammalian target of rapamycin (mTOR) pathway has been identified as a…”
Get full text

Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib by Blay, J.-Y.

“…The efficacy and tolerability of the receptor tyrosine kinase inhibitor, sunitinib malate, have been demonstrated in phase I–III clinical trials of patients…”
Get full text

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival by Italiano, A., Toulmonde, M., Cioffi, A., Penel, N., Isambert, N., Bompas, E., Duffaud, F., Patrikidou, A., Lortal, B., Le Cesne, A., Blay, J.-Y., Maki, R.G., Schwartz, G.K., Antonescu, C.R., Singer, S., Coindre, J.-M., Bui, B.

“…Data regarding the role of systemic therapy in patients with advanced well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS) are limited. From 2000 to…”
Get full text